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ABSTRACT
The aim of the present work was to develop and characterisation 
of stable ethosomal formulation as a carrier for transdermal 
delivery of paroxetine hydrochloride. to prepare this ethosome, 
different concentrations of soya lecithin and ethanol were taken. 
Vesicular size, polydispersity index, zeta potential, entrapment 
effiency were determined by photon correlation spectroscopy 
and ultracentrifugation techniques. The in vitro permeation 
study across human cadaver skin was done. Stability study was 
done on optimised F2 formulation. The vesicle size decreases 
as an increase in the concentration of ethanol. entrapment 
efficiency increases with the increase in concentration of soya 
lecithin. The ethosome exhibit entrapment efficiency of 40-
64%. In vitro permeation study across human skin ethosome F2 
formulation showed higher transdermal flux 29.64% µg/cm2/hr. 
The release mechanism of in vitro permeation shows zero order 
drug release from the formulation. In vivo pharmacodyanamic 
study F2 formulation showed significant immobility as 
compared to control group. Stability study results revealed 
no significant change found in vesicle size distribution and 
polydispersity index. Our result indicates that the developed 
ethosomal system may be potential and safe for the delivery of 
paroxetine hydrochloride through skin. 
Keywords: ethosome, transdermal, Paroxetine hydrochloride, 
Soya lecithin, Cholesterol.
1. InTRoduCTIon
In recent years the attraction of lipid vesicle use in delivery 
system for skin treatment is increasing (1, 2). Paroxetine 
hydrochloride (PXH) is a selective serotonin reuptake 
inhibitor. Commonly available in tablets and capsule dosage 
form, but its oral administration has numbers of side effects 
as well as it undergoes extensive hepatic metabolism. 
Variation in plasma concentration and long term therapy 
leads to severe side effects (3).    
to overcome these difficulties such as extensive hepatic 
first pass metabolism transdermal delivery is beneficial (4). 
The useful of transdermal release has been reported for 
some antidepressants (5, 6). It has previously reported that 
significant increase delivery of drugs across the skin would be 
done by using an ethosomes as novel permeation enhancing 
carrier (7-10). ethosomes are soft, malleable vesicles used 
for delivery of drugs to reach the deep skin (11). Solubility 
and high encapsulation efficiency values for large range of 
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lipophilic drugs can be obtained due to presence of ethanol. 
The vesicles with soft flexible characteristics are formed due 
to the presence of ethanol, which permit them to go through 
more simply into the deeper layers of the skin (12). The 
present aim focuses on the preparation and characterization 
of ethosomal formulation for PXH transdermal delivery. The 
aim of the present study was to develop stable ethosomes 
carrier for transdermal delivery of PXH. The effect of ethanol 
and soya lecithin on the permeation of PXH through the 
human skin was evaluated.
2. MATeRIAlS And MeThodS
2.1 Material
Paroxetine hydrochloride (PXH) was a gift sample from 
Zyduscadila Healthcare Ltd. Soya lecithin was purchased 
from research Lab Mumbai. ethanol was purchased from 
Loba chemical Mumbai. Cholesterol was purchased from 
research Lab Fine Chem Industries, Mumbai. Peg-400 was 
purchased from Dipa Laboratory Chemicals. all materials 
and solvents used in this study are of analytical grade.
2.2 Preparation of ethosomes
Soya lecithin, cholesterol and PXH were dissolved in ethanol 
then addition of propylene glycol. Double distilled water was 
added slowly with a fine stream in above ethanol dispersion 
with constant mixing at 700 rpm on a magnetic stirrer, in 
a well-sealed glass container. Mixing was continued for an 
additional 5 min. The system was kept at 300C throughout the 
preparation and was then left to cool at room temperature. 
(7, 8). The compositions of all ethosomal formulations are 
shown in table. 1.
Table 1. Composition of ethosomal formulations.
Code Paroxetine 
hCI%
Soya 
lecithin%
Cholesterol% ethanol Propylene 
glycol
F1 2% 1% 2% 30% 0.5%
F2 2% 1% 2% 35% 0.5%
F3 2% 1.5% 1% 30% 0.5%
F4 2% 1.5% 1% 35% 0.5%
F5 2% 2% 2% 30% 0.5%
F6 2% 2% 1% 35% 0.5%
2.3 Characterisation of ethosome
2.3.1 Vesicles size distribution, polydispersity index (PI) 
and zeta potential
The vesicle size distribution, polydispersity index and 
zeta potential of vesicles were determined using photon 
correlation spectroscopy (Beckmann counter, Delsa Nano, 
uSa). The formulation were diluted by 1/4th distilled 
water before measurement and measured three times at a 
scattering angle of 900. The polydispersity index (PI) was 
used as a measurement of the width of the size distribution. 
PI less than 0.4 indicates a homogenous and monodisperse 
population. Zeta potential was measured as the particle 
electrophoretic mobility means of laser microelectrophoresis 
in a thermostated cell.
2.3.2 Entrapment efficiency (EE)
The entrapment capacity of PXH by ethosomal vesicles was 
determined by ultracentrifugation. The drug containing 
ethosomal formulations were kept overnight at 4°C and 
centrifuge in ultracentrifuge (tarsons) 12000 rpm for 30 
min. The supernatant was removed and drug amount was 
determined by using uV-Visible spectrophotometer at 
294 nm in both the sediment and the supernatant. The 
entrapment capacity was calculated as follows, [(T-S) /T] 
*100, where T is the total amount of drug that is detected 
both in the supernatant and sediment, and S is the amount of 
drug found in the supernatant (13).
2.3.3 In vitro permeation study
2.3.3.1 Preparation of cadaver skin
The human cadaver skin sample provided from government 
Medical College and Hospital, aurangabad. The human 
cadaver skin contained same subcutaneous fat which was 
carefully trimmed and then rinse with normal saline, 
prepared skin was wrapped in aluminium foil and stored at 
-20 °C until use (14).
2.3.3.2 Procedure
Franz diffusion cell was used to carry out the in vitro skin 
permeation study having an effective diffusion area 0.785 cm2 
and having a receptor compartment volume of 15 ml. The 
cadaver skin was brought to room temp and mounted with the 
donor compartment dry and open to the atmosphere. Initially, 
the donor compartment was empty and receiver compartment 
was filled with phosphate buffer pH 7.4. The receiver fluid was 
stirred with magnetic bead with the speed of 100 rpm and the 
temperature was maintained at 37 1 . The phosphate buffer 
pH 7.4 was replaced with the fresh buffer at every 30 min. 
No peak was found that after 3 hours indicating complete 
stabilisation of skin. a 5 ml formulation was placed into 
the donor compartment and sealed with paraffin film to 
provide occlusive condition. The samples were withdrawn 
at regular interval for 10 hrs filtered through 0.45 . 
membrane filter and analysed for drug amount by uV-Visible 
spectrophotometer at 294 nm.
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2.3.4 Permeation data analysis
The cumulative amount of penetrant, Q (g/cm2), which 
permeated the skin per unit surface area was plotted against 
time. The linear portion of the plot was taken as being the 
steady-state flux, (Js). The permeability coefficient (Kp) was 
calculated as (15),
Kp = Js/Cv
Where Cv is the concentration of penetrant in the donor 
solution.
2.3.5 In vivo pharmacodynamic study
approval to carry out pharmacodynamics studies was 
obtained (Institutional animals ethical Committee, approved 
the protocol). Forced Swim test (FSt) was used to evaluate 
the antidepressant effect of the optimized F2 formulation. 
rats of either sex weighing 250–300 g were kept under 
standard laboratory conditions (temperature 23-30oC).The 
rats were kept with free access to standard laboratory diet. 
approximately 14 cm2 of the abdominal side of rats skin was 
shaved on the in each group except group treated with the 
marketed tablet formulation. 
rats were divided randomly into three groups each containing 
six animals. group 1 was considered as a control. group 2 
was treated with oral tablets of PXH containing 1.40 mg/
day and administered without anaesthesia by using simple 
poly-ethylene tube. group 3 was treated with the optimized 
F2 formulation applied transdermally containing 2 mg/day 
(equivalent to 0.60 mg/day) drug. 
2.3.6 Force swim test
rats were forced to swim in a cylindrical glass tank (60 
cm height X 30 cm in diameter) containing water after the 
administration of doses. The water was filled up to 40 cm 
height so they were swim without touching their hind limb or 
tail to the bottom of the tank. On the 1st day of experiments, 
rats were forced to swim for 10 min. after 24 h, rats were re-
exposed to forced swim for 5 min and animals were judged 
for immobility, climbing, and swimming. after a 5-min swim 
test, the rat was removed from the cylinder, dried and then 
returned to its home cage. (16)
2.3.7 Vesicle stability study
Stability of optimised F2 formulation was kept at room 
temp for 3 weeks. Vesicle size and polydispersity index were 
measured at 1, 2, 3, 7, 14 and 21 days and mean value is used 
for the analysed of the data.
3. ReSulT And dISCuSSIon
3.1 Vesicle size, polydispersity index and zeta potential
The vesicle mean diameters for all formulations are shown in 
table 2. The result of photon correlation spectroscopy shows 
narrow peak for all formulations, which indicating that the 
size of vesicle population is comparatively uniform in size. In 
accordance with other researcher, this decrease in the mean 
diameter of the vesicle is due to the presence of ethanol. 
Higher concentration of ethanol produced lower vesicle size. 
Probably the ethanol causes the modification of the net charge 
of the system and confer it some degree of stearic stabilization 
(10). Polydispersity index of formulations is shown in table 
2. Compare to all formulations F2 formulation showed a 
less polydispersity index is 0.23 indicates a homogeneous 
population of ethosome vesicle that may finally lead to 
decrease in mean particle size. In the formulation the 
concentration of ethanol increases from 30-35% the 
significant decrease in vesicle size. On the other hand, it was 
observed that the increase in soya lecithin concentration 
resulted in an increase in mean particle size. Small vesicle 
size is formed with the F2 formulation having a 1% of soya 
lecithin and 35% ethanol. twice fold increase in soya lecithin 
concentration (1%-2%) resulted in two fold increase in 
ethosomes size (from 501.33nm ±1.92 - 1314.33nm±3.5). 
The charge of vesicles is an important parameter that can 
influence both stability and skin vesicle interaction. The zeta 
potential value of all formulations shown in table 2. The 
concentration of ethanol increase from 30-35% v/v resulting 
in an increase in zeta potential values. Polydispersity index 
was determined as a measure of homogeneity in formulation. 
Polydispersity index ≤ 0.3 indicate homogeneous population 
of ethosome vesicle in formulation Ps.
Table 2. Particle size, polydispersity index, zeta potential, 
flux and permeability coefficient of formulations.
Code Particle
Size (nm)
Polydispersity
Index
Zeta
potential
(mV)
Flux (µg/
cm2/hr)
Permeability 
coefficient
(x10-3)(cm/hr)
F1 697±0.04 0.473±0.004 -22.26 12.94 1.2
F2 501.33±1.92 0.25±0.02 -16.10 29.64 2.9
F3 1126. 33±450 1.06±1.004 -25.48 24.87 2.4
F4 1125.66±4.04 0.691±2.004 -24.93 19.46 1.9
F5 1314.33±3.5 0.622±2.004 -28.46 16.40 1.6
F6 1249.33±4.5 0.957±0.0052 -16.81 24.07 2.4
Values are expressed in mean ±SD, n=3
3.2 entrapment efficiency
The entrapment efficiency of all formulations shown in 
Figure 1.  entrapment efficiency of formulation containing 
of 1% soya lecithin and 30% ethanol (F1) was found to be 
60%, which significantly increased to 64% when the amount 
of ethanol increases to 35% (F2) keeping the concentration 
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of soya lecithin constant. ethosomes formulation prepared 
with 1.5% soya lecithin and 30% ethanol (F3) exhibited 40% 
entrapment efficiency, which was increased to 45% (F4) 
respectively; keep the amount of soya lecithin constant. 
Formulation prepared with 2% soya lecithin and 30% ethanol 
(F5) showed 42% entrapment efficiency, which was increased 
to 61% when the concentration of ethanol increased to 35% 
(F6) respectively. These data supported by previous findings 
that solubility and high encapsulation efficiency values 
for large range of lipophilic drugs can be obtained due to 
presence of ethanol (13). From these results entrapment 
efficiency of formulation was observed due to increase in 
ethanol concentration.
 
Figure 1. % entrapment efficiency of all formulation.
3.3 In vitro permeation study
In vitro skin permeation experiment was performed using 
human cadaver skin showed that permeation was highest 
in F2 formulation as shown in Figure 2. Flux value of 
F2 formulation was significantly higher when compared 
with other formulation (P≤0.05) as shown in above table 
2. Highest flux value 29.64 of F2 as compared to other 
formulation. These may be due to small vesicle size and 
high entrapment efficiency along with high concentration 
of ethanol. These data supported by previous findings that 
ethanol interact with a lipid molecules of stratum corneum, 
resulting in a reduction in the tm of stratum corneum, 
increase in there fluidity. The intercalation of ethanol due to 
the polar head group environment can result in an increase 
in membrane permeability (17). It may also suggest that 
mixing of phospholipids with the stratum corneum lipid 
of the intercellular layers enhances the permeability of the 
skin (18).  F2 formulation was selected as an optimized 
formulation from the vesicle size distribution, polydispersity 
index, zeta potential, drug entrapment efficiency, and in vitro 
permeation study results and considered for further study. 
Figure 2. In vitro skin permeation profile of PXH through 
human cadaver skin.
3.4 In vivo Pharmacodynamic study
The pharmacodynamic activity of the ethosomes F2 
formulation was compared with orally administered dose. 
The force swim test is most widely used pharmacodynamic 
activity model for assessing the antidepressant activity. The 
total immobility period would decrease if high concentrations 
of paroxetine hydrochloride reached target site. 
3.5 Force swim test
results of FSt confirmed that there was significant reduction 
in the total immobility period in seconds by treating the 
rats by transdermal ethosomal F2 formulation. There was 
significant (p<0.001) differences in the total immobility 
period of control compared with paroxetine hydrochloride 
treated group as shown in table 3. ethosomes formulation 
significantly (p<0.001) reduced total immobility period by 
33.73 sec than orally treated group.
Table 3. results of FSt study
Treatment group Total immobility (sec) Mean
Control 180 188 179 179.66±8.5
Paroxetine 
hydrochloride oral 
administration
140 150 148 148.33±7.63
F2 through transdermal 
route 112 107 125 114.66±9.29
Values are expressed in mean ±SD, n=3, P value<0.05 
considered statistically significant
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 3.6 Vesicle stability study
The results of stability study of vesicles of ethosomes system 
are shown in table 4. Size distribution study of system of 
ethosomes was investigated by using photon correlation 
spectroscopy. There was no significant change in mean 
vesicles size and polydispersity index of F2 formulation for 
a period of 4 weeks.  
Table 4. Mean particles size and polydispersity index after 21 
days of optimized formulation
days Mean diameter (nm) Polydispersity index
1 501.33±1.92 0.252±0.012
2 501.99±0.036 0.255±0.018
3 502.36±0.01 0.258±0.025
7 502.7±0.026 0.60±0.015
14 503.78±0.03 0.605±0.024
21 505.58±0.025 0.610±0.026
Values are expressed in mean ±SD, n=3
4. ConCluSIon
ethosomal vesicles with appropriate size and maximum 
drug entrapment efficiency can be prepared. F2 formulation 
showed highest transdermal flux across human skin 
was composed of 1% soya lecithin, 35% ethanol and 2% 
cholesterol. In vivo pharmacodyanamic study of optimised 
formulation showed significant values compared to control 
group. Therefore, it can be concluded from the result of 
the study that ethosome formulation is a potentially useful 
carrier for transdermal delivery of paroxetine hydrochloride 
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